SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-102855"
 

Search: onr:"swepub:oai:DiVA.org:uu-102855" > Greater reduction o...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Braun, OscarLund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine (author)

Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease

  • Article/chapterEnglish2008

Publisher, publication year, extent ...

  • 2008
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-102855
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-102855URI
  • https://doi.org/10.1160/TH08-05-0313DOI
  • https://lup.lub.lu.se/record/1284847URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Prasugrel, a novel P2Y(12) ADP-receptor antagonist, has been reported to achieve greater inhibition of platelet aggregation compared to clopidogrel as assessed by light transmission aggregometry. It was the objective of this study to investigate the effect of prasugrel on alternative markers of platelet activation in comparison to a high loading dose and the approved maintenance dose of clopidogrel. One hundred ten aspirin-treated patients with stable coronary artery disease were randomized to a loading dose (LD, day 1)/ maintenance dose (MD, days 2-29) of prasugrel 60 mg/10 mg or clopidogrel 600 mg/75 mg. Platelet activation markers were analyzed by whole blood flow cytometry pre-dose and at 2 and 24 hours after LD and pre-dose at 14 and 29 days. After stimulation with 20 muM ADP, 2 hours after LD, significantly lower expression of activated GPIIb/IIIa (4.3 vs. 21.8 [mean fluorescent intensity (MFI)], p < 0.001) and P-selectin (2.0 vs. 11.7 MFI, p < 0.001) along with decreased formation of platelet-monocyte aggregates (16.4% vs. 29.6% positive cells, p < 0.001) was observed with prasugrel versus clopidogrel. All these effects were maintained through 24 hours and during the MD period. In conclusion, prasugrel 60 mg LD and 10 mg MD inhibit several markers of platelet activation and the formation of platelet-monocyte aggregates more effectively than a 600 mg LD and 75 mg MD of clopidogrel. Attenuated platelet aggregation and reduced expression of platelet pro-coagulant and pro-inflammatory markers with prasugrel suggest the potential to reduce cardiovascular events both in the acute setting and in long-term treatment.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Johnell, MatildaUppsala universitet,Institutionen för medicinska vetenskaper (author)
  • Varenhorst, ChristophUppsala universitet,Institutionen för medicinska vetenskaper,UCR(Swepub:uu)chrva923 (author)
  • James, Stefan,1964-Uppsala universitet,Institutionen för medicinska vetenskaper,UCR(Swepub:uu)stjam367 (author)
  • Brandt, John T. (author)
  • Jakubowski, Joseph A. (author)
  • Winters, Kenneth J. (author)
  • Wallentin, Lars,1943-Uppsala universitet,Institutionen för medicinska vetenskaper,UCR(Swepub:uu)larswall (author)
  • Erlinge, DavidLund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)kard-der (author)
  • Siegbahn, Agneta,1947-Uppsala universitet,Institutionen för medicinska vetenskaper(Swepub:uu)agsie424 (author)
  • KardiologiSektion II (creator_code:org_t)

Related titles

  • In:Thrombosis and Haemostasis100:4, s. 626-6330340-62452567-689X

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view